Third-quarter results will be released before the market opens Nov. 5

LifeStance Health Group (LFST) will release its Q3 2026 earnings on Nov. 5 before market open and host a conference call at 8:30 a.m. ET. The company is a major provider of outpatient mental healthcare with over 8,500 employees across 35 states.

Original reporting
Published Oct 15, 2026, 8:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 8:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$LFST
Neutral
medium confidence
Mentioned
$LFST
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$LFSTNeutralMed
01

Why it matters

The main tradable element is timing. The market will likely reprice expectations for Q3 performance and any updated outlook when the release hits pre-market on Nov. 5.

02

Market read

A single-name earnings timing update that can drive pre-earnings positioning and volatility, without providing new financial results.

03

What to watch

Traders may still need to monitor pre-announcement materials (slides, supplemental metrics) that are posted on the IR site prior to the call, which could contain incremental detail not captured here.

Relevance 4/10Novelty 3/10Timing: earnings release scheduled before market opens Nov. 5, 2026

Background

LifeStance is an outpatient mental healthcare provider; this release notice schedules its Q3 2026 earnings and conference call.

Company-level read

Ticker impact

$LFSTNeutralMedium confidence
Context

LifeStance Health Group will release its Q3 2026 earnings before the market opens on Nov. 5, with a live call at 8:30 a.m. ET.

Expected impact

Likely volatility increase into Nov. 5 as traders position for the Q3 print and management commentary.

Evidence & confidence

The article provides the exact release timing and call details but no earnings numbers, guidance, or new fundamental information.

Market effects

May modestly affect sentiment and volatility in outpatient mental healthcare names around the earnings calendar, but no sector-wide new data is provided.

No specific regional market impact is indicated beyond standard earnings-calendar effects.

Primarily a US-listed single-name catalyst; no global macro or cross-market linkage is described.

Counterpoint

Because the release date is already a calendar item and the article contains no results or guidance, the incremental trading edge may be limited versus broader earnings-volatility models.

Key entities

  • LifeStance Health Group, Inc.

    NASDAQ-listed outpatient mental healthcare provider issuing Q3 2026 earnings before market opens Nov. 5, 2026.

  • LFST

    LifeStance Health Group equity ticker referenced in the release notice.

Related articles

$LFSTMed

BMO raises Lifestance Health stock price target on strong results

BMO Capital raised its price target on Lifestance Health (LFST) to $16.00, citing strong Q3 results. Revenue beat estimates by 5.6%, and EBITDA exceeded by 23.6%. The company raised its full-year outlook, but expects a sequential EBITDA decline due to reinvestment. LFST trades at $13.43 with a $5.1B market cap. The company also announced Q3 2026 earnings, surpassing expectations with a 25% revenue increase.

$LFSTMed

What LifeStance Health Group (LFST) Said on Its Q3 Earnings Call

LifeStance Health Group (LFST) forecasted Q4 revenue of $446M-$466M and adjusted EBITDA of $56M-$64M. The company expects a 1-2% reduction in 2027 revenue growth due to a new electronic health record system. LifeStance expanded specialty services, including TMS and SPRAVATO, and plans to continue acquisitions and center openings. Management expects specialty services revenue to reach $70M this year, up from $50M in 2025.

$LFSTMed

LifeStance Health Group Inc (LFST) (Q3 2026) Earnings Call Highlights: Revenue Jumps 25%

LifeStance Health (LFST) reported 25% revenue growth in Q3 2026. The company expects EHR implementation to reduce 2027 revenue growth by 1-2% and cost $20-30M. Clinician retention is stable, but new clinician retention is low. Q4 adjusted EBITDA guidance suggests a sequential decline due to planned investments. Specialty services, including Spravato, are growing but face variable payer reimbursement. Management remains optimistic about long-term margin expansion and clinician growth.

$LFSTHighAI 8/10

LifeStance (LFST) Q3 2026 Earnings Call Transcript

LifeStance (LFST) reported Q3 2026 revenue growth of 25% to $456M, driven by increased visit volumes and higher revenue per visit. The company expanded its clinician base by 11% and opened 8 new centers. It also raised full-year revenue guidance to $1.741B-$1.761B. LifeStance highlighted strong results in specialty services for treatment-resistant depression and plans to invest in strategic priorities. The company expects temporary revenue growth impact in 2027 due to EHR implementation.

$LFSTMed

LifeStance Health: Q3 Earnings Snapshot

LifeStance Health Group Inc. (LFST) reported Q3 net income of $22.4M, or 6 cents per share, beating estimates. Revenue was $455.9M, also exceeding forecasts. The company expects Q4 revenue of $446M-$466M and full-year revenue of $1.74B-$1.76B.